CN Patent

CN112218636B — 使用川地匹坦进行治疗的方法

Assigned to University of Kentucky Research Foundation · Expires 2025-05-06 · 1y expired

What this patent protects

本文公开了治疗正经历或有风险经历阿片样物质使用的不期望后果的个体，和治疗正经历或有风险经历对阿片样物质的渴望的个体的方法，以及NK‑1受体拮抗剂川地匹坦在治疗所述个体中的应用。

USPTO Abstract

本文公开了治疗正经历或有风险经历阿片样物质使用的不期望后果的个体，和治疗正经历或有风险经历对阿片样物质的渴望的个体的方法，以及NK‑1受体拮抗剂川地匹坦在治疗所述个体中的应用。

Drugs covered by this patent

Patent Metadata

Patent number: CN112218636B
Jurisdiction: CN
Classification: —
Expires: 2025-05-06
Drug substance claim: No
Drug product claim: No
Assignee: University of Kentucky Research Foundation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.